These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 26440421)
1. Emerging immunopharmacological targets in multiple sclerosis. Farjam M; Zhang GX; Ciric B; Rostami A J Neurol Sci; 2015 Nov; 358(1-2):22-30. PubMed ID: 26440421 [TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of multiple sclerosis: the state of the art. Karussis D BioDrugs; 2013 Apr; 27(2):113-48. PubMed ID: 23423844 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis. Orthmann-Murphy JL; Calabresi PA Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128 [TBL] [Abstract][Full Text] [Related]
9. New therapeutic approaches for multiple sclerosis. De Jager PL; Hafler DA Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332 [TBL] [Abstract][Full Text] [Related]
10. New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. Vidal-Jordana A Neurol Clin; 2018 Feb; 36(1):173-183. PubMed ID: 29157398 [TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. De Santi L; Polimeni G; Cuzzocrea S; Esposito E; Sessa E; Annunziata P; Bramanti P Curr Med Chem; 2011; 18(12):1775-84. PubMed ID: 21466473 [TBL] [Abstract][Full Text] [Related]
12. [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]. Kleinschnitz C; Meuth SG; Kieseier BC; Wiendl H Nervenarzt; 2007 Aug; 78(8):883-911. PubMed ID: 17551708 [TBL] [Abstract][Full Text] [Related]
13. Established and novel disease-modifying treatments in multiple sclerosis. Cross AH; Naismith RT J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048 [TBL] [Abstract][Full Text] [Related]
14. Central nervous system infections - a potential complication of systemic immunotherapy. Hemmer B; Frohman E; Hartung HP; Stüve O Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834 [TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple sclerosis. Anlar O CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):167-74. PubMed ID: 19601814 [TBL] [Abstract][Full Text] [Related]
16. Current and future treatments for relapsing-remitting multiple sclerosis. Birnbaum G Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055 [TBL] [Abstract][Full Text] [Related]
18. Promoting remyelination in multiple sclerosis: current drugs and future prospects. Kremer D; Küry P; Dutta R Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245 [TBL] [Abstract][Full Text] [Related]
19. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Gholamzad M; Ebtekar M; Ardestani MS; Azimi M; Mahmodi Z; Mousavi MJ; Aslani S Inflamm Res; 2019 Jan; 68(1):25-38. PubMed ID: 30178100 [TBL] [Abstract][Full Text] [Related]